Premium
Deubiquitinases as Anticancer Targets of Gold Complexes
Author(s) -
Zou Taotao,
Zhang JingJing,
Cao Bei,
Tong KaChung,
Lok ChunNam,
Che ChiMing
Publication year - 2016
Publication title -
israel journal of chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.908
H-Index - 54
eISSN - 1869-5868
pISSN - 0021-2148
DOI - 10.1002/ijch.201600044
Subject(s) - auranofin , chemistry , cisplatin , gold compounds , enzyme , ligand (biochemistry) , dithiocarbamate , combinatorial chemistry , in vivo , dna damage , biochemistry , dna , stereochemistry , receptor , organic chemistry , rheumatoid arthritis , medicine , surgery , microbiology and biotechnology , chemotherapy , biology
Metal‐based anticancer agents with non‐DNA targets are anticipated for overcoming cisplatin resistance problems. Gold complexes are generally known to undergo ligand exchange or redox reactions with thiols, and hence, are potentially useful agents that could target thiol‐containing enzymes, but not DNA. Recent studies have shown that deubiquitinases (DUBs), key enzymes regulating proteasome‐related protein homeostasis, are potential anticancer targets of both gold(I) and gold(III) complexes. In this review, the current status of gold complexes as DUB inhibitors is discussed. In particular, auranofin and cyclometalated gold(III) complexes containing dithiocarbamate ligands (e.g., [(Au III (C N)(DEDT)] + , HC N=2‐phenylpyridine, DEDT=diethyldithiocarbamate) are highlighted as examples of DUB inhibitors. The mechanisms of their anticancer action, together with in vitro and/or in vivo antitumor potencies, are also explored.